The PE ratio measures the
reported earnings of a company to its current stock price. While earnings are
easy to manipulate on the balance sheet, this ratio gives you a sense of what
buyers are willing to pay for the stock—what they believe it will do in
the future.
Comparing a stock's PE to the average PE of companies in its industry gives
you a sense of market sentiment about the stock and how well it fares
financially. It's not the only number, nor the most important, but comparing
similar companies is valuable. A ratio far above or below that of its peers is
significant.
Industries are more specific than sectors, so companies within most
industries are more similar than are companies within an industry. Be aware
that the size and customers of companies are important to their prospects.
The PE ratio measures the
reported earnings of a company to its current stock price. While earnings are
easy to manipulate on the balance sheet, this ratio gives you a sense of what
buyers are willing to pay for the stock—what they believe it will do in
the future.
Comparing a stock's PE to the average PE of companies in its sector gives
you a sense of market sentiment about the stock and how well it fares
financially. It's not the only number, nor the most important, but comparing
similar companies is valuable. A ratio far above or below that of its peers is
significant.
Be aware that sectors are very broad, with many types of companies in the
same sector.
The free cash flow
jitter of a stock measures how much the company's free cash flow varies
from its historical trend, on average. While it's always nice to make more
money than you expected, a company with predictable free cash flow is stable
and good. A company with wild swings in its free cash flow warrants further
research.
Open-market buys and sells reported by Axsome Therapeutics's
officers, directors, and 10% owners on SEC Form 4. Routine transactions
(tax withholding, option exercises, and stock grants) are excluded --
these are discretionary trades only.
Date
Insider
Type
Shares
Price
2026-07-01T00:00:00
TABUTEAU HERRIOT (Chief Executive Officer)
Sell
49,666
$240.25
2026-06-11T00:00:00
JEFFS ROGER
Sell
286
$249.12
2026-06-10T00:00:00
Coleman Mark
Sell
643
$249.00
2026-06-10T00:00:00
JEFFS ROGER
Sell
286
$246.18
2026-06-10T00:00:00
Mahony Susan
Sell
300
$246.18
2026-06-09T00:00:00
TABUTEAU HERRIOT (Chief Executive Officer)
Sell
49,670
$241.01
2026-06-09T00:00:00
Mahony Susan
Sell
300
$237.21
2026-06-09T00:00:00
Pizzie Nick (Chief Financial Officer)
Sell
33,000
$240.09
2026-06-02T00:00:00
Coleman Mark
Sell
5,537
$223.39
2026-06-01T00:00:00
Coleman Mark
Sell
6,000
$230.30
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where
they bought it. Maybe there are financial problems, or maybe there's a value
play.
As of the latest analysis, there are 3,024,030 shares shorted. With 43,556,575 shares available for purchase and an average trading
volume over the past 10 trading days of 676,380, it would take at least 4.471 days for all of the short holders to cover their
shorts.
Based on our analysis, we believe that you should not buy Axsome Therapeutics
right now. It might be a good stock to own—we just can't prove
it with value analysis right now. Proceed with caution.
Does Axsome Therapeutics have a coherent story? Does it have a plan to
continue to make money? Is it worth your time? Only you can decide where to go
from here. Our investment guide helps you ask the
right questions, including how to buy stocks.
Use these research links for more information.
We don't yet have enough
financial history for Axsome Therapeutics to produce a full worked example.
Check back as more data becomes available, or see the current price and
research links below.